| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41575-019-0132-Z |
| P698 | PubMed publication ID | 30903105 |
| P2093 | author name string | Ronald J Sokol | |
| Amy G Feldman | |||
| P2860 | cites work | Neonatal cholestasis | Q80945524 |
| Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference | Q81753891 | ||
| Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening | Q83747342 | ||
| Selective use of endoscopic retrograde cholangiopancreatography in the diagnosis of biliary atresia in infants younger than 100 days | Q84401207 | ||
| Comparison of different diagnostic methods for differentiating biliary atresia from idiopathic neonatal hepatitis | Q84784853 | ||
| Shear wave elastography helps differentiate biliary atresia from other neonatal/infantile liver diseases | Q85343346 | ||
| Newborn Bilirubin Screening for Biliary Atresia | Q88095507 | ||
| Nuclear receptors and liver disease: Summary of the 2017 basic research symposium | Q91059985 | ||
| Identification of Polycystic Kidney Disease 1 Like 1 Gene Variants in Children With Biliary Atresia Splenic Malformation Syndrome | Q91140075 | ||
| Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action | Q24613405 | ||
| High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 | ||
| Recent advances in understanding and managing cholestasis | Q26748537 | ||
| The SPLIT research agenda 2013 | Q26825184 | ||
| New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond | Q27013066 | ||
| Sequencing technologies - the next generation | Q27860568 | ||
| Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care | Q28075831 | ||
| Bile acid nuclear receptor FXR and digestive system diseases | Q28085493 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice | Q30535328 | ||
| Portal hypertension in children and young adults with biliary atresia | Q33402861 | ||
| Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease | Q33805839 | ||
| Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1 | Q33929416 | ||
| Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan | Q34153781 | ||
| Cholangiocyte biology and cystic fibrosis liver disease | Q34464126 | ||
| The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased glutathione and SOX17 | Q34522256 | ||
| Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. | Q34590786 | ||
| Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial | Q34999853 | ||
| Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation | Q35631885 | ||
| Intestinal Microbiota, Lipids, and the Pathogenesis of Intestinal Failure-Associated Liver Disease | Q35679248 | ||
| PoopMD, a Mobile Health Application, Accurately Identifies Infant Acholic Stools. | Q35722159 | ||
| Molecular Genetic Dissection and Neonatal/Infantile Intrahepatic Cholestasis Using Targeted Next-Generation Sequencing | Q35917843 | ||
| Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth | Q36071207 | ||
| Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy | Q36104831 | ||
| Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates | Q36263626 | ||
| Whatever happened to "neonatal hepatitis"? | Q36352863 | ||
| Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. | Q36464051 | ||
| Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada | Q44920745 | ||
| Percutaneously inserted central catheter for total parenteral nutrition in neonates: complications rates related to upper versus lower extremity insertion | Q46090187 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation | Q46673007 | ||
| 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice | Q46939923 | ||
| Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations | Q47137137 | ||
| Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. | Q48250842 | ||
| Percutaneous cholecysto-cholangiography in the diagnosis of obstructive jaundice in infants | Q48925836 | ||
| Reducing the Underimmunization of Transplant Recipients | Q50077047 | ||
| Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate | Q50438744 | ||
| Newborn Direct or Conjugated Bilirubin Measurements As a Potential Screen for Biliary Atresia. | Q50896607 | ||
| Cost-effective analysis of screening for biliary atresia with the stool color card. | Q51053787 | ||
| Universal screening for biliary atresia using an infant stool color card in Taiwan. | Q51114193 | ||
| Neonatal Cholestasis. | Q51340539 | ||
| Role of abdominal sonography in the preoperative diagnosis of extrahepatic biliary atresia in infants younger than 90 days. | Q51376366 | ||
| Transient cholestasis in newborn infants with perinatal asphyxia. | Q51678912 | ||
| Province-Wide Biliary Atresia Home Screening Program in British Columbia: Evaluation of First Two Years. | Q52640526 | ||
| Inborn Errors of Metabolism with Hepatopathy: Metabolism Defects of Galactose, Fructose, and Tyrosine. | Q52675188 | ||
| Neonatal Cholestasis. | Q54236162 | ||
| Association of variants of ABCB11 with transient neonatal cholestasis. | Q54277571 | ||
| Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome | Q57070329 | ||
| Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis | Q57105327 | ||
| Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders | Q57122674 | ||
| EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis | Q59384401 | ||
| Contribution of acoustic radiation force impulse (ARFI) elastography to the ultrasound diagnosis of biliary atresia | Q60691307 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Biliary atresia: the Canadian experience | Q79949877 | ||
| 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps | Q80407604 | ||
| Biliatresone, a Reactive Natural Toxin from Dysphania glomulifera and D. littoralis: Discovery of the Toxic Moiety 1,2-Diaryl-2-Propenone | Q36585337 | ||
| Increased frequency of double and triple heterozygous gene variants in children with intrahepatic cholestasis | Q36753645 | ||
| Nuclear receptors as drug targets in cholestatic liver diseases | Q36786270 | ||
| Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. | Q36895500 | ||
| Jaundice in babies: implications for community screening for biliary atresia | Q36903399 | ||
| Newborn Screening for Biliary Atresia | Q37036993 | ||
| Medical treatment of cholestatic liver disease | Q37074707 | ||
| Mechanisms of disease: Inborn errors of bile acid synthesis | Q37199631 | ||
| Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium | Q37435062 | ||
| Recent insights into the function and regulation of the bile salt export pump (ABCB11). | Q37580701 | ||
| Parenteral nutrition-associated cholestasis in premature babies: risk factors and predictors | Q37621499 | ||
| Liver fibrosis in biliary atresia | Q37763083 | ||
| HIDA, percutaneous transhepatic cholecysto-cholangiography and liver biopsy in infants with persistent jaundice: can a combination of PTCC and liver biopsy reduce unnecessary laparotomy? | Q37904859 | ||
| Accuracy of hepatobiliary scintigraphy for differentiation of neonatal hepatitis from biliary atresia: systematic review and meta-analysis of the literature | Q38092007 | ||
| Long term outcomes after pediatric liver transplantation | Q38186718 | ||
| The therapeutic potential of chemical chaperones in protein folding diseases. | Q38211124 | ||
| Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. | Q38331124 | ||
| Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. | Q38333973 | ||
| Incidence of Biliary Atresia and Timing of Hepatoportoenterostomy in the United States | Q38660435 | ||
| Biliary atresia and other cholestatic childhood diseases: Advances and future challenges. | Q38831107 | ||
| Cholestasis in Preterm Infants | Q38846691 | ||
| Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and N | Q38901059 | ||
| Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study. | Q38989429 | ||
| Hospitalizations for Respiratory Syncytial Virus and Vaccine-Preventable Infections in the First 2 Years After Pediatric Liver Transplant | Q39020496 | ||
| New therapeutic concepts in bile acid transport and signaling for management of cholestasis. | Q39044702 | ||
| Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis | Q39062043 | ||
| A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. | Q39471132 | ||
| Stool color card screening for biliary atresia | Q39693838 | ||
| A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis. | Q40082820 | ||
| Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis | Q40183754 | ||
| Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice | Q40215280 | ||
| Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3 | Q40628895 | ||
| Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor | Q40768989 | ||
| Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing. | Q41221551 | ||
| Late referral for biliary atresia--missed opportunities for effective surgery | Q41823817 | ||
| Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis | Q41871213 | ||
| Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes | Q41977878 | ||
| Jaundice at 14 days of age: exclude biliary atresia | Q42129961 | ||
| Analysis of gene mutations in children with cholestasis of undefined etiology | Q42728589 | ||
| Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. | Q43240642 | ||
| Improving outcomes of biliary atresia: French national series 1986-2009. | Q43638929 | ||
| Niemann-pick disease type C in neonatal cholestasis at a North American Center | Q44079921 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 346-360 | |
| P577 | publication date | 2019-06-01 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics | |
| P478 | volume | 16 |
| Q91642461 | Inherited Cholestatic Diseases in the Era of Personalized Medicine |
| Q104283798 | Modeling Outcomes in Children With Biliary Atresia With Native Liver After 2 Years of Age |
| Q101133373 | Molecular and cellular mechanisms of liver fibrosis and its regression |
| Q97646037 | Neonatal Cholestasis Over Time: Changes in Epidemiology and Outcome in a Cohort of 154 Patients From a Portuguese Tertiary Center |
| Q97593197 | Pediatric Cholestasis: Epidemiology, Genetics, Diagnosis, and Current Management |
| Q98185020 | The Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury |
Search more.